

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/51414175>

ChemInform Abstract: Cytotoxic Calanquinone A from *Calanthe arisanensis* and Its First Total Synthesis

ARTICLE in BIOORGANIC & MEDICINAL CHEMISTRY LETTERS · AUGUST 2008

Impact Factor: 2.42 · DOI: 10.1016/j.bmcl.2008.06.099 · Source: PubMed

CITATIONS

11

READS

30

9 AUTHORS, INCLUDING:



Kyoko Nakagawa-Goto

Kanazawa University

77 PUBLICATIONS 813 CITATIONS

SEE PROFILE



Donglei Yu

U.S. Food and Drug Administration

36 PUBLICATIONS 991 CITATIONS

SEE PROFILE



Yi-Nan Liu

Beijing Medical University

31 PUBLICATIONS 510 CITATIONS

SEE PROFILE



Susan Morris-Natschke

University of North Carolina at Chapel Hill

189 PUBLICATIONS 3,795 CITATIONS

SEE PROFILE

Published in final edited form as:

Bioorg Med Chem Lett. 2008 August 1; 18(15): 4275–4277. doi:10.1016/j.bmcl.2008.06.099.

Cytotoxic Calanquinone A from *Calanthe arisanensis* and Its First Total Synthesis

Chia-Lin Lee^{a,b}, Kyoko Nakagawa-Goto^a, Donglei Yu^a, Yi-Nan Liu^a, Kenneth F. Bastow^c, Susan L. Morris-Natschke^a, Fang-Rong Chang^b, Yang-Chang Wu^{b,d*}, and Kuo-Hsiung Lee^{a*}

^aNatural Products Research Laboratories, School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA

^bGraduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807, Taiwan

^cDivision of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA

^dCenter of Excellence for Environmental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan

Abstract

Calanquinone A (**1**) was isolated from an EtOAc-soluble extract of *Calanthe arisanensis* through bioassay-guided fractionation. Its structure was identified by spectroscopic methods. Compound **1** showed potent cytotoxicity (EC₅₀ < 0.5 μg/mL) against lung (A549), prostate (PC-3 and DU145), colon (HCT-8), breast (MCF7), nasopharyngeal (KB), and vincristine-resistant nasopharyngeal (KB-VIN) cancer cell lines, and interestingly, showed an improved drug resistance profile compared to paclitaxel. The total synthesis of **1** was also achieved and reported herein.

The *Calanthe* genus in the Orchidaceae family contains terrestrial perennial herbs that are widely distributed from tropical Africa and Madagascar to tropical and subtropical Asia, China, Japan, southward through Malaysia and Indonesia to the Pacific islands and Australia. This genus includes more than 150 species, but only nineteen are found in Taiwan. Among them *Calanthe arisanensis* Hayata is endemic to Taiwan and grows in forests from 1000 to 2000 m throughout the island.¹

A phytochemical study of this plant has not been reported to date. In cytotoxicity screening of extracts of Formosan plants, an EtOAc extract of *C. arisanensis* was found to be active against various human cancer cell lines with IC₅₀ < 20 μg/mL. Bioassay-directed chromatographic fractionation of this extract produced a new phenanthraquinone calanquinone A (**1**). Compound **1** showed significant in vitro cytotoxic activity against seven human cancer cell lines, as described below.

The active MeOH extract (225 g) of dry roots of *C. arisanensis* (5.42 kg) was partitioned between EtOAc and water (1:1, v/v). Further fractionation of the active EtOAc extract (32.7 g) by repeated liquid chromatography on silica gel gave calanquinone A (**1**). HRESIMS of **1**

*Corresponding authors. K.H.L. Tel: 919-962-0066; fax: 919-966-3893; e-mail: khlee@unc.edu, Y.C.W. 886-7-312-1101 ext. 2197. Fax: 886-7-311-4773; e-mail: yachwu@kmu.edu.tw.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

showed a $[M-H]^-$ ion at m/z 313.0705 ($C_{17}H_{14}O_6-H$), indicating 11 degrees of unsaturation. The IR spectrum showed absorptions for hydroxyl (3348 cm^{-1}), carbonyl (1642 cm^{-1}), and aromatic ring ($1626, 1514, 1460, 1411, \text{ and } 844\text{ cm}^{-1}$) functional groups. UV absorptions at 242, 308, and 426 nm also indicated an aromatic system. Seventeen carbon signals, including three methoxy, four methine, and ten quaternary carbons, were observed in the NMR spectra of **1** (Table 1). Among the ten quaternary carbons, two were identified as carbonyl carbons on the basis of chemical shifts δ_C 184.7 and 186.2. Therefore, the data supported the presence of two carbonyls, six olefins, and three ring moieties to fulfill the 11 degrees of unsaturation, and **1** was postulated to be an phenanthrenedione or anthrenedione.² 1D NMR and HSQC data indicated the presence of three methoxy groups at δ_H 3.96, 4.01, and 4.02 (δ_C 57.1, 56.2, and 61.0), one pair of *ortho*-coupled aromatic protons at δ_H 8.05 (d, $J=8.7\text{ Hz}$, δ_C 137.1) and 8.10 (d, $J=8.7\text{ Hz}$, δ_C 122.0), and two olefinic protons at δ_H 6.15 (s, δ_C 107.4) and 6.86 (s, δ_C 101.4). In the HMBC spectra, the olefinic proton at δ_H 6.86 exhibited 2J interactions with a carbon at δ_C 155.2 (C-7), as well as 3J interactions with carbons at δ_C 118.7 (C-4b), 140.4 (C-6), and 137.1 (C-9). The other olefinic proton at δ_H 6.15 exhibited 2J interactions with a carbon at δ_C 161.7 (C-3), as well as 3J interactions with carbons at δ_C 186.2 (C-4) and 133.0 (C-10a). Locations of methoxy groups at C-3, C-6, and C-7 were confirmed by the following NOESY correlations: δ_H 6.15 (H-2)/3.96 (3-OMe), δ_H 6.86 (H-8)/4.01 (7-OMe) and 8.05 (H-9), δ_H 4.01 (7-OMe)/4.02 (6-OMe), and δ_H 8.05 (H-9)/8.10 (H-10). Thus, compound **1** was identified as 5-hydroxy-3,6,7-trimethoxy-1,4-phenanthrenequinone and has been named as calanquinone A (**1**).

Compound **1** is related in structure to other naturally occurring phenanthrenequinones, including the des-oxy analog sphenone (lacking the C-5 OH group),³ cymbinodin A (lacking the two methoxy groups at C-6 and C-7),⁴ and annoquinone A (lacking any substituents on ring C).^{5,6} In prior studies, sphenone and annoquinone A showed cytotoxic activity against the KB cell line (reported EC_{50} 2.7³ and 1.6⁵ $\mu\text{g/mL}$, respectively).

Compound **1** exhibited potent cytotoxicity (EC_{50} 0.03–0.45 $\mu\text{g/mL}$) against human lung (A549), prostate (PC-3 and DU145), colon (HCT-8), breast (MCF7), nasopharyngeal (KB), and vincristine-resistant nasopharyngeal (KB-VIN) cancer cell lines. Paclitaxel was used as a positive control (data shown in Table 2). Interestingly, **1** exhibited comparable potency against both KB and its drug-resistant KB-VIN subline, and thus, showed an improved drug resistance profile compared to paclitaxel. The cytotoxic values demonstrate the strong potential of **1** as a promising lead compound and *C. arisanensis* as a promising plant source of new agents for cancer chemotherapy.

In order to make sufficient quantities of **1** for extensive biological evaluation, we modified the synthetic procedure of Kraus and co-workers^{7,8} (Scheme 1) to synthesize **1**. As shown in Scheme 2, we prepared 2-methoxy-5-carboxylic acid methyl ester-1,4-quinone (**4**)⁹ by AgO oxidation of the methyl ester (**3**) of commercially available 2,4,5-trimethoxybenzoic acid (**2**). Compound **4** was coupled with 3,4,5-trimethoxytoluene in the presence of 1 equiv. of trifluoroacetic acid to produce quinone **5**, although Kraus reported the production of hydroquinone **10** under these reaction conditions (Scheme 1). The quinone skeleton of **5** was confirmed from ^{13}C -NMR data, which showed two carbonyl groups at 180.6 and 183.6 ppm. In addition, reaction of **5** with Me_2SO_4 did not give a methoxylated product (i.e., **11** in Scheme 1). We attempted to reduce **5** with $\text{Na}_2\text{S}_2\text{O}_4$ to obtain the corresponding hydroquinone, which could be transformed to the Kraus type of intermediate **11** ($R = \text{OMe}$) after methylation. Despite extending the reaction time and adding more reducing agent, only starting material was recovered.

Therefore, **5** was reduced with LAH (THF, reflux, 1 h) to alcohol, which was oxidized selectively to aldehyde **6** with activated MnO_2 (toluene, 110 $^\circ\text{C}$, overnight) (Scheme 2). After

an unsuccessful attempt to obtain the phenanthraquinone **9** directly from **6** using $P_4.tBu$, quinone **6** was first reduced to the hydroquinone using aq. $Na_2S_2O_4$ (CH_2Cl_2 , rt., overnight), ¹⁰ and then methylated with Me_2SO_4 in the presence of K_2CO_3 (acetone, 60 °C, 1.5 h) to give the desired compound **7** (Scheme 2). Cyclization of **7** with $P_4.t Bu$ (benzene, 100 °C, 63 h) gave **8**, which was oxidized with AgO (6N HNO_3 , acetone, 50 °C, 2–3 min) to phenanthraquinone **9**. Compound **9** was converted to calanquinone A (**1**) by selective demethylation with TMSI in CH_2Cl_2 at r.t. (Scheme 2).

Synthesized **1** and intermediates **5–9** were screened in an *in vitro* cytotoxicity assay (data shown in Table 3). Compound **1** exhibited the highest potency (EC_{50} 0.15–0.75 $\mu g/mL$) against all seven tested cancer cell lines. The remaining compounds showed no (**6–8**) or only weak (**5** and **9**) activity. Clearly, the potency of **1** merits further study and our synthetic route can efficiently produce sufficient quantities of **1** for future extensive biological evaluation and SAR investigation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by grants from National Cancer Institute, NIH, USA (CA 17625, K. H. Lee), National Science Council, Taiwan (Y.-C. Wu) and KMU-EM-97-2.1.b (Y.-C. Wu).

References and notes

1. Boufford, DE.; Hsieh, C-F.; Huang, T-C.; Kuoh, C-S.; Ohashi, H.; Su, H-J.; Yeh, H-Y.; Hsiao, J-L.; Hsiao, S-H. Flora of Taiwan. Vol. 5. Taipei, Taiwan: Editorial Committee of the Flora of Taiwan; 2000. p. 776-777.p. 782-783.
2. Fan C, Wang W, Wang Y, Qin G, Zhao W. Phytochemistry 2001;57:1255. [PubMed: 11454354]
3. Wu TS, Huang SC, Chen MT, Jong TT. Phytochemistry 1989;28:1280.
4. Barula AK, Ghosh BB, Ray S, Patra A. Phytochemistry 1990;29:3056.
5. Wu TS, Jong TT, Tien HJ, Kuoh CS, Furukawa H, Lee KH. Phytochemistry 1987;26:1623.
6. Krohn K, Looock U, Paavilainen K, Hausen B, Schmalle HW, Kiesele H. ARKIVOC 2001;2:88.
7. Kraus GA, Hoover K, Zhang N. Tetrahedron Lett 2002;43:5319.
8. Kraus GA, Zhang N. Tetrahedron Lett 2002;43:9597.
9. Parker KA, Spero DM, Koziski KA. J. Org. Chem 1987;52:183.
10. Hormi OEO, Moilanen AM. Tetrahedron 1998;54:1943.





Figure 1.
Structure of calanquinone A (**1**).



Scheme 1.
Synthetic procedure of Kraus.


**Scheme 2.**Our total synthesis of calanquinone A (**1**).

Table 1NMR data of calanquinone A (**1**)^a

Proton	¹³ C (δ _C)	¹ H (δ _H)	HMBC (¹³ C no)	NOESY (¹ H no)
1	184.7			
2	107.4	6.15 s	3, 4, 10a	C ₃ -OCH ₃
3	161.7			
4	186.2			
4a	128.3			
4b	118.7			
5	148.3			
6	140.4			
7	155.2			
8	101.4	6.86 s	4b, 6, 7, 9	9, C ₇ -OCH ₃
8a	135.1			
9	137.1	8.05 d (8.7)	4b, 8, 10a	8, 10
10	122.0	8.10 d (8.7)	1, 4a, 8a	9
10a	133.0			
-OCH ₃	C ₃ -OCH ₃ 57.1 C ₆ -OCH ₃ 61.0 C ₇ -OCH ₃ 56.2	C ₃ -OCH ₃ 3.96 s C ₆ -OCH ₃ 4.02 s C ₇ -OCH ₃ 4.02 s	3 6 7	2 C ₇ -OCH ₃ 8, C ₆ -OCH ₃
C ₅ -OH		10.73		

^a Measured in CDCl₃ (300 and 500 MHz, δ in ppm, *J* in Hz).

Table 2
Cytotoxicity of calanquinone A (**1**) isolated from *C. arisanensis*

Compound	EC ₅₀ (μg/mL) / Cell line					
	A549	PC-3	DU145	HCT-8	MCF-7	KB-VIN
Calanquinone A (1)	0.19	0.16	0.34	0.20	0.03	0.45
Paclitaxel ^a	<0.005	0.0097	<0.005	0.21	0.0072	2.16

^a positive control

Table 3

Cytotoxicity of synthesized **1** and related intermediates

Compound	EC ₅₀ (μg/mL) / Cell line					
	A549	PC3	DU145	HCT8	MCF7	KB-VIN
1	0.31	0.75	0.48	0.29	0.15	0.24
5	6.12	6.09	4.74	5.85	6.40	5.48
6	NA	NA	NA	NA	NA	NA
7	NA	NA	NA	NA	NA	NA
8	NA	NA	NA	NA	NA	NA
9	7.06	7.81	4.40	15.25	5.33	9.14

NA: no activity up to 20 μg/mL